Press "Enter" to skip to content

APCCC 2019: De Novo Oligometastatic Prostate Cancer: Consensus and Controversy on Aims, Options and Rationale – UroToday

admin 0

APCCC 2019: De Novo Oligometastatic Prostate Cancer: Consensus and Controversy on Aims, Options and Rationale  UroToday

Basel, Switzerland (UroToday.com) Michael Morris, MD, discussed de novo oligometastatic prostate cancer at the APCCC 2019 session on PSA recurrence after …

“prostate cancer” – Google News

(Visited 2 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *